[1]
|
Beyene, G. and Tsegaye, W. (2011) Bacterial Uropathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern in Jimma University Specialized Hospital, Southwest Ethiopia. Ethiopian Journal of Health Sciences, 21, 141-146. http://dx.doi.org/10.4314/ejhs.v21i2.69055
|
[2]
|
Rüden, H., Gastmeier, P., Daschner, F.D. and Schumacher, M. (1997) Nosocomial and Community-Acquired Infections in Germany. Summary of the Results of the First National Prevalence Study (NIDEP). Infection, 25, 199-202. http://dx.doi.org/10.1007/BF01713142
|
[3]
|
Maki, D.G. and Tambyah, P.A. (2001) Engineering out the Risk for Infection with Urinary Catheters. Emerging Infectious Disease, 7, 342-347. http://dx.doi.org/10.3201/eid0702.010240
|
[4]
|
Tambyah, P., Olyszyna, D.P., Tenke, P. and Koves, P. (2010) Urinary Catheters and Drainage Systems: Definition, Epidemiology and Risk Factors. In: Naber, K.G., Schaeffer, A.J., Heyns, C., Matsumoto, T., et al., Eds., Urogenital Infections, European Association of Urology, Arnhem, 523-531.
|
[5]
|
Gupta, K. (2003) Emerging Antibiotic Resistance in Urinary Tract Pathogens. Infectious Disease Clinics of North America, 17, 243-259. http://dx.doi.org/10.1016/S0891-5520(03)00006-0
|
[6]
|
Auer, S., Wojna, A. and Hell, M. (2010) Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli. Antimicrobial Agents and Chemotherapy, 54, 4006-4008. http://dx.doi.org/10.1128/AAC.01760-09
|
[7]
|
Tsukamoto, N., Ohkoshi, Y., Okubo, T., Sato, T., Kuwahara, O., Fujii, N., Tamura, Y. and Yokota, S. (2013) High Prevalence of Cross-Resistance to Aminoglycosides in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates. Chemotherapy, 59, 379-384.
|
[8]
|
Michalopoulos, A.S., Livaditis, I.G. and Gougoutas, V. (2011) The Revival of Fosfomycin. International Journal of Infectious Diseases, 15, e732-e739. http://dx.doi.org/10.1016/j.ijid.2011.07.007
|
[9]
|
Parker, S., Lipman, J., Koulenti, D., Dimopoulos, G. and Roberts, J.A. (2013) What Is the Relevance of Fosfomycin Pharmacokinetics in the Treatment of Serious Infections in Critically Ill Patients? A Systematic Review. International Journal of Antimicrobial Agents, 42, 289-293. http://dx.doi.org/10.1016/j.ijantimicag.2013.05.018
|
[10]
|
Falagas, M.E., Kastoris, A.C., Kapaskelis, A.M. and Karageorgopoulos, D.E. (2010) Fosfomycin for the Treatment of Multidrug-Resistant, Including Extended-Spectrum Beta-Lactamase Producing, Enterobacteriaceae Infections: A Systematic Review. The Lancet Infectious Diseases, 10, 43-50. http://dx.doi.org/10.1016/S1473-3099(09)70325-1
|
[11]
|
Oteo, J., Orden, B., Bautista, V., Cuevas, O., Arroyo, M., Martínez-Ruiz, R., Pérez-Vázquez, M., Alcaraz, M., García-Cobos, S. and Campos, J. (2009) CTX-M-15 Producing Urinary Escherichia coli O25b-ST131-Phylogroup B2 Has Acquired Resistance to Fosfomycin. Journal of Antimicrobial Chemotherapy, 64, 712-717. http://dx.doi.org/10.1093/jac/dkp288
|
[12]
|
Karageorgopoulos, D.E., Wang, R., Yu, X.H. and Falagas, M.E. (2012) Fosfomycin: Evaluation of the Published Evidence on the Emergence of Antimicrobial Resistance in Gram-Negative Pathogens. Journal of Antimicrobial Chemotherapy, 67, 255-268. http://dx.doi.org/10.1093/jac/dkr466
|
[13]
|
(2013) CDC/NHSN Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in Acute Care Setting. www.INICC.org
|
[14]
|
Horan, T.C., Andrus, M. and Dudeck, M.A. (2008) CDC/NHSN Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in Acute Care Setting. American Journal of Infection Control, 36, 309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002
|
[15]
|
Collee, J.G., Miles, R.S. and Watt, B. (1996) Tests for the Identification of Bacteria. In: Collee, J.G., Marmion, B.P., Fraser, A.G. and Simmons, A., Eds., Mackie & McCartney Practical Medical Microbiology, 14th Edition, Churchill Livingstone, New York, 131-151.
|
[16]
|
Chessbrough, M. (1993) Collection, Transport and Examination of Specimens. In: Chessbrough, M., Eds., Medical Laboratory Manual for Tropical Countries, Butterworth-Heinemann, Oxford, 100-195.
|
[17]
|
Clinical and Laboratory Standards Institute (2013) Performance Standards for Antimicrobial Susceptibility Testing. 23rd Informational Supplement, CLSI Document M100-S23, CLSI, Wayne.
|
[18]
|
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Plasmid Vectors. In: Nolan, C. and Ferguson, M., Eds., Molecular Cloning. A laboratory Manual, 2nd Edition, Cold Spring Harbour, New York, 3-110.
|
[19]
|
Gray, K.J., Gascoyne-Binzi, D.M., Nicholson, P., Heritage, J. and Hawkey, P.M. (2001) Transmissible Fosfomycin Resistance Markers in Urinary Isolates and Imported Food Stuffs in the UK during 1994 and 1995. Journal of Antimicrobial Chemotherapy, 48, 744-745. http://dx.doi.org/10.1093/jac/48.5.744
|
[20]
|
Garcia, P., Arca, P., Toyos, J.R. and Suarez, J.E. (1994) Detection of Fosfomycin Resistance by the Polymerase Chain Reaction and Western Blotting. Journal of Antimicrobial Chemotherapy, 34, 955-963. http://dx.doi.org/10.1093/jac/34.6.955
|
[21]
|
Zilhao, R. and Courvalin, P. (1990) Nucleotide Sequence of the fosB Gene Conferring Fosfomycin Resistance in Staphylococcus epidermidis. FEMS Microbiology Letters, 56, 267-272.
|
[22]
|
Hou, J., Huang, X., Deng, Y., He, L., Yang, T., Zeng, Z., Chen, Z. and Liu, J.H. (2012) Dissemination of the Fosfomycin Resistance Gene fosA3 with CTX-M β-Lactamase Genes and rmtB Carried on IncFII Plasmids among Escherichia coli Isolates from Pets in China. Antimicrobial Agents and Chemotherapy, 56, 2135-2138. http://dx.doi.org/10.1128/AAC.05104-11
|
[23]
|
National Nosocomial Infections Surveillance S. (2004) National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992 through June 2004, Issued October 2004. American Journal of Infection Control, 32, 470-485. http://dx.doi.org/10.1016/j.ajic.2004.10.001
|
[24]
|
Malhotra, V.L., Khandpur, N., Dass, A. and Mehta, G. (2008) Prevalence of Extended Spectrum Beta-Lactamases Producing Clinical Isolates from Patients of Urinary Tract Infection in a Tertiary Care Hospital in Delhi. Journal of Communicable Diseases, 40, 269-272.
|
[25]
|
Tariq, T.M. (2014) Occurrence of Extended-Spectrum B-Lactamase Producers among Enterobacteriaceae in a Paediatric Tertiary Care Facility in Kabul. Journal of the College of Physicians and Surgeons Pakistan, 24, 530-531.
|
[26]
|
Harris, P.N., Tambyah, P.A. and Paterson, D.L. (2015) β-Lactam and β-Lactamase Inhibitor Combinations in the Treatment of Extended-Spectrum β-Lactamase Producing Enterobacteriaceae: Time for a Reappraisal in the Era of Few Antibiotic Options? The Lancet Infectious Diseases, 15, 475-485. http://dx.doi.org/10.1016/S1473-3099(14)70950-8
|
[27]
|
Jiang, Y., Shen, P., Wei, Z., Liu, L., He, F., Shi, K., Wang, Y., Wang, H. and Yu, Y. (2015) Dissemination of a Clone Carrying a fosA3-Harbouring Plasmid Mediates High Fosfomycin Resistance Rate of KPC-Producing Klebsiella pneumoniae in China. International Journal of Antimicrobial Agents, 45, 66-70. http://dx.doi.org/10.1016/j.ijantimicag.2014.08.010
|
[28]
|
Chen, Y.H., Hsueh, P.R., Badal, R.E., Hawser, S.P., Hoban, D.J., Bouchillon, S.K., Ni, Y. and Paterson, D.L. (2011) Antimicrobial Susceptibility Profiles of Aerobic and Facultative Gram-Negative Bacilli Isolated from Patients with Intra-Abdominal Infections in the Asia-Pacific Region According to Currently Established Susceptibility Interpretive Criteria. Journal of Infection, 62, 280-291. http://dx.doi.org/10.1016/j.jinf.2011.02.009
|
[29]
|
Paterson, D.L. and Bonomo, R.A. (2005) Extended-Spectrum Beta-Lactamases: A Clinical Update. Clinical Microbiology Reviews, 18, 657-686. http://dx.doi.org/10.1128/CMR.18.4.657-686.2005
|
[30]
|
Paladin Labs (2007) Monurol Package Insert. Paladin Labs, Quebec.
|
[31]
|
Pullukcu, H., Tasakan, M., Sipahi, O.R., Yamazhan, T., Aydemir, S. and Ulusoy, S. (2007) Fosfomycin in the Treatment of Extended Spectrum Beta-Lactamase-Producing Escherichia coli-Related Lower Urinary Tract Infections. International Journal of Antimicrobial Agents, 29, 62-65. http://dx.doi.org/10.1016/j.ijantimicag.2006.08.039
|
[32]
|
Wienke, M., Pfeifer, Y., Weissgerber, P., Marschal, M., Autenrieth, I.B. and Grobner, S. (2012) In Vitro Activity of Tigecycline and Molecular Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates from a University Hospital in South-Western Germany. Chemotherapy, 58, 241-248. http://dx.doi.org/10.1159/000339488
|
[33]
|
Demir, T. and Buyukguclu, T. (2013) Evaluation of the in Vitro Activity of Fosfomycin Tromethamine against Gram Negative Bacterial Strains Recovered from Community and Hospital-Acquired Urinary Tract Infections in Turkey. International Journal of Infectious Diseases, 17, e966-e970. http://dx.doi.org/10.1016/j.ijid.2013.04.005
|
[34]
|
Sun, F., Chen, S., Qiu, X., Sun, Y., Feng, W., Chen, J. and Xia, P. (2014) Antibacterial Activity of Fosfomycin against Uropathogens. Chemotherapy, 60, 157-161. http://dx.doi.org/10.1159/000371734
|
[35]
|
Linsenmeyer, K., Strymish, J., Weir, S., Berg, G., Brecher, S. and Gupta, K. (2015) Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 60, 1134-1136. http://dx.doi.org/10.1128/AAC.02614-15
|
[36]
|
Lee, S.Y., Park, Y.J., Yu, J.K., Jung, S., Kim, Y., Jeong, S.H. and Arakawa, Y. (2012) Prevalence of Acquired Fosfomycin Resistance among Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates in Korea and IS26-Composite Transposon Surrounding fosA3. Journal of Antimicrobial Chemotherapy, 67, 2843-2847. http://dx.doi.org/10.1093/jac/dks319
|
[37]
|
Reeves, D.S. (1994) Fosfomycin Trometamol. Journal of Antimicrobial Chemotherapy, 34, 853-858. http://dx.doi.org/10.1093/jac/34.6.853
|
[38]
|
Etienne, J., Gerbaud, G., Courvalin, P. and Fleurette, J. (1989) Plasmid-Mediated Resistance to Fosfomycin in Staphylococcus epidermidis. FEMS Microbiology Letters, 52, 133-137. http://dx.doi.org/10.1111/j.1574-6968.1989.tb03566.x
|
[39]
|
Thompson, M.K., Keithly, M.E., Harp, J., Cook, P.D., Jagessar, K.L., Sulikowski, G.A. and Armstrong, R.N. (2013) Structural and Chemical Aspects of Resistance to the Antibiotic Fosfomycin Conferred by fosB from Bacillus cereus. Biochemistry, 52, 7350-7362. http://dx.doi.org/10.1021/bi4009648
|
[40]
|
Horii, T., Kimura, T., Sato, K., Shibayama, K. and Ohta, M. (1999) Emergence of Fosfomycin-Resistant Isolates of Shiga-Like Toxin-Producing Escherichia coli O26. Antimicrobial Agents and Chemotherapy, 43, 789-793.
|
[41]
|
Walsh, C.C., McIntosh, M.P., Peleg, A.Y., Kirkpatrick, C.M. and Bergen, P.J. (2015) In Vitro Pharmacodynamics of Fosfomycin against Clinical Isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 70, 3042-3050. http://dx.doi.org/10.1093/jac/dkv221
|